**Q** What treatments relieve arthritis and fatigue associated with systemic lupus erythematosus?

**EVIDENCE-BASED ANSWER**

**A** Hydroxychloroquine and chloroquine improve the arthritis associated with mild systemic lupus erythematosus (SLE)—producing a 50% reduction in arthritis flares and articular involvement—and have few adverse effects (strength of recommendation [SOR]: A, systematic review of randomized controlled trials [RCTs]).

Methotrexate reduces arthralgias by as much as 79%, but produces adverse effects in up to 70% of patients (SOR: B, systematic review of RCTs with limited patient-oriented evidence).

Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are often used for SLE joint pain (SOR: C, expert opinion).

Omega-3 fatty acids may reduce arthritis symptoms by about 35% (SOR: B, RCTs with inconsistent evidence).

Abatacept and dehydroepiandrosterone don’t produce clinically meaningful improvements in fatigue associated with SLE, and abatacept causes significant adverse effects (SOR: B, posthoc analysis of a single RCT).

Aerobic exercise may help fatigue (SOR: B, systematic review with inconsistent evidence).

**Evidence summary**

A systematic review of pharmacotherapy for joint pain in patients with SLE found 4 poor-quality RCTs that evaluated hydroxychloroquine, chloroquine, and methotrexate.1 Of the 2 studies that examined the effect of hydroxychloroquine, one (47 patients) showed a statistically significant 50% reduction in SLE flares (including arthritis, pleuritis, and cutaneous symptoms) over 24 weeks in patients treated with hydroxychloroquine compared with placebo (TABLE1). The second study (71 subjects) found a nonquantified decrease in self-reported pain when hydroxychloroquine was compared with placebo, although some of the patients were also taking prednisone (10 mg/d).

An RCT that evaluated the effect of chloroquine showed a statistically significant reduction in unspecified “articular involvement” compared with placebo.

The fourth RCT, assessing methotrexate, found a statistically significant reduction by as much as 79% in patients with residual arthritis or arthralgia at 6 months compared with placebo, although 70% of patients taking methotrexate developed significant adverse effects, including infections, gastrointestinal symptoms, and elevated transaminases compared with 14% on placebo (number needed to harm [NNH]=2).

The authors of the review noted that consensus opinion holds that oral corticosteroids and NSAIDs reduce SLE-associated joint pain, but they found no studies that objectively evaluated either of these interventions.1

**Fish oil also helps arthritis**

Two RCTs on the effects of 3 g/d of omega-3 polyunsaturated fatty acids (fish oil) for 24 weeks in SLE patients with mild disease found a reduction in Systemic Lupus Activity Measure-Revised (SLAM-R) scores.2,3
<table>
<thead>
<tr>
<th>Treatment*</th>
<th>Study type</th>
<th>Intervention/total number of subjects</th>
<th>Duration</th>
<th>Target symptom</th>
<th>Outcomes measure</th>
<th>Effect size favoring treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxychloroquine¹</td>
<td>RCT</td>
<td>25/47</td>
<td>24 wk</td>
<td>SLE flares¹</td>
<td>Reduction in SLE symptoms</td>
<td>NNT=3</td>
</tr>
<tr>
<td>Chloroquine¹</td>
<td>RCT</td>
<td>11/23</td>
<td>12 mo</td>
<td>SLE activity</td>
<td>SLEDAI score increase ≥3 points</td>
<td>NNT=2</td>
</tr>
<tr>
<td>Methotrexate¹</td>
<td>RCT</td>
<td>19/38</td>
<td>6 mo</td>
<td>Arthritis or arthralgia</td>
<td>Reported symptoms</td>
<td>NNT=2</td>
</tr>
<tr>
<td>Dehydroepiandrosterone⁵</td>
<td>RCT</td>
<td>30/60⁶</td>
<td>12 mo</td>
<td>Fatigue</td>
<td>Change in multidimensional fatigue inventory scale (4-20 points)</td>
<td>NS</td>
</tr>
<tr>
<td>Exercise bike 30 min 3 times/wk⁴</td>
<td>RCT</td>
<td>16/34</td>
<td>24 wk</td>
<td>Fatigue</td>
<td>Change in 2 fatigue scales</td>
<td>NS</td>
</tr>
<tr>
<td>Exercise treadmill 30 min 3 times/wk vs no exercise⁶</td>
<td>QE (not randomized)</td>
<td>41/60</td>
<td>12 wk</td>
<td>Fatigue</td>
<td>Change in fatigue severity scale</td>
<td>NS</td>
</tr>
<tr>
<td>Aerobic exercise 30-50 min 3 times/wk (intervention) vs no exercise (control)⁶,⁷</td>
<td>RCT</td>
<td>33/65</td>
<td>12 wk</td>
<td>Fatigue</td>
<td>Change in Chalder fatigue scale (0-33 points)</td>
<td>7- vs 3-point improvement in average scores favoring intervention (P=.04)</td>
</tr>
<tr>
<td>Group self-management sessions (2-hr session/wk)⁵,⁸</td>
<td>QE (not randomized)</td>
<td>21/41</td>
<td>6 wk</td>
<td>Fatigue</td>
<td>Change in multidimensional assessment of fatigue scale (4-50 points)</td>
<td>Average 6.7-point improvement (NS)</td>
</tr>
<tr>
<td>Fish oil²</td>
<td>RCT</td>
<td>27/52</td>
<td>24 wk</td>
<td>SLE activity</td>
<td>Reduction in SLAM-R score</td>
<td>Improved; 1.4-point reduction</td>
</tr>
<tr>
<td>Fish oil³</td>
<td>RCT</td>
<td>30/60</td>
<td>24 wk</td>
<td>SLE activity</td>
<td>Reduction in SLAM-R score</td>
<td>Improved; 3.1-point reduction</td>
</tr>
<tr>
<td>Abatacept⁴</td>
<td>RCT</td>
<td>118/175</td>
<td>12 mo</td>
<td>SLE flares</td>
<td>Reduction of flares</td>
<td>NS</td>
</tr>
</tbody>
</table>

NNT, number needed to treat; NS, not significant; QE, quasi-experimental; RCT, randomized controlled trial; SLAM-R, Systemic Lupus Activity Measure-Revised; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Index (scale not defined).

* Treatment comparison was placebo unless otherwise specified.
† SLE flares: arthritis, pleuritis, and cutaneous symptoms.
‡ All 60 subjects were women with inactive SLE.
SLAM-R is a validated measure of SLE disease activity, rated on a scale from 0 to 10, including 23 clinical and 7 laboratory manifestations of disease.

In the first study (52 subjects), disease activity decreased from an average SLAM-R score of 6.1 at baseline to 4.7 ($P<.05$). The second study (60 subjects) found a similar reduction in mean SLAM-R scores from 9.4 to 6.3 ($P<.001$) and joint pain scores from 1.27 to 0.83 ($P=.047$).

**Drug treatments don’t significantly relieve fatigue**

An industry-sponsored RCT that compared abatacept with placebo found improvements in fatigue that weren’t clinically meaningful in posthoc analysis (-9.45 points difference on a self-reported 0-to-100 visual analog scale; 95% confidence interval, -17.65 to -1.25, with a 10-point reduction considered to be clinically meaningful). Abatacept also had a high rate of serious adverse events, including facial edema, polyneuropathy, and serious infections (24/121 with abatacept vs 4/59 placebo; NNH=8).4

Another RCT found no effect of dehydroepiandrosterone on fatigue in women with inactive SLE.5

**Nondrug treatments for fatigue produce mixed results**

Studies of nondrug treatment of SLE-associated fatigue show inconsistent results. A systematic review of nonpharmacologic interventions for fatigue in several chronic diseases found 2 RCTs and 4 quasi-experimental studies that included 324 patients with SLE.6 Of 4 studies that evaluated the effect of exercise, 2 showed improvement and 2 didn’t. Neither group self-management nor relaxation therapy and telephone counseling significantly relieved fatigue.6-8 A small RCT (24 patients) found no benefit for acupuncture over sham needling in treating pain and fatigue in SLE.9

**Recommendations**

The American College of Rheumatology guideline for referral and management of SLE states that “NSAIDs are sometimes helpful for control of fever, arthritis, and mild serositis. Antimalarial agents (eg, hydroxychloroquine) are useful for skin and joint manifestations of SLE, for preventing flares, and for other constitutional symptoms of the disease. They may also reduce fatigue.”10

The European League Against Rheumatism recommends antimalarials or glucocorticoids to treat patients with SLE without major organ manifestations. They also say clinicians may try NSAIDs for limited periods of time in patients at low risk for the drugs’ complications.11

---

**Methotrexate reduced arthralgias by as much as 79%, but produced adverse effects in up to 70% of patients.**